CAR T-Cell Clinical Research Trials
Immunotherapy
Program
How is Immunotherapy Different from Conventional Cancer Treatment?
Why Refer/Choose Northside Hospital’s Immunotherapy Program?
Immunotherapy Patients Have Access To:
_____
How Does CAR T-Cell Therapy Work?
CAR T-Cell Treatment
CAR T-Cell Commercial Products
CAR T-Cell Clinical Research Trials
| Trial Number | Name of Trial | Drug & Link to clinicaltrials.gov |
|---|---|---|
| NHL CAR T-cell Clinical Research Trials- September 15, 2021 | ||
| NSH1170 | A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells, in Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma | JCAR017 NCT02631044 |
| NSH1226 | An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | JCAR017 NCT03331198 |
| NSH 1251 | A Phase 1, Multicenter, Open-Label Study of CC-97540, C19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | CC-97540 NCT04231747 |
| Multiple Myeloma CAR T-cell Clinical Research Trials- September 15, 2021 | ||
| NSH1216 | A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (rrMM) (KarMMa-3) | bb2121 NCT03651128 |
| NSH1277 | A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High-Risk Newly Diagnosed Multiple Myeloma (KarMMa-4) | bb2121 NCT04196491 |